BDMD · Baird Medical Investment Holdings Ltd · Documents

$0.10 -0.01 (-6.99%)

Market Cap

$3.45M

32.11M

Volume · Nov 12 101.84M Avg daily vol (3M) 15.19M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $22.54M down 39.2% 20-F filed Apr 24, 2026

2026

Nov 5

Current report 6-K

Minimum bid-price deficiency leaves listing status unchanged

Baird Medical Investment Holdings Limited received Nasdaq’s November 2, 2026 notice of a minimum bid-price deficiency; its shares continue trading under “BDMD.” It has 180 calendar days, until May 3, 2027, to regain compliance, with a possible additional 180-day grace period.

4 source passages

NEW YORK, November 4, 2026 – Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated November 2, 2026 notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This notification does not result in the delisting of the Company’s shares, and Baird Medical’s shares will continue to trade, uninterrupted, on the Nasdaq Capital Market under the ticker “BDMD”. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until Monday, May 3, 2027, to regain compliance with the minimum bid price rule. In the event the Company does not regain compliance with the minimum bid price requirement by Monday, May 3, 2027, the Company may be eligible for an additional 180 calendar day grace period to regain compliance, or may face delisting. Open the document at this passage

Sep 30

Current report 6-K

Current report

Baird Medical Investment Holdings Limited agreed on September 24, 2026 to sell a senior 8% original issue discount convertible note in the principal amount of US$4,347,826, convertible into shares, and issue 110,070 discount shares for an additional 2% original issue discount.

Read from the first part of this long document

Sep 30

Current report 6-K

Current report

Baird Medical Investment Holdings Limited reported revenue of $9,915,407 and net income attributable to shareholders of $35,405 for the six months ended June 30, 2026, versus revenue of $7,959,494 and a net loss of $11,293,895 for 2025.

Read from the first part of this long document

Sep 3

Current report 6-K

Current report AI summary on its way

Aug 6

Registration statement F-3/A

Registration statement AI summary on its way

Jul 27

Annual report 20-F/A FY2025, ended Dec 31

Annual report for FY2025 AI summary on its way

Revenue $22.54M ▼ 39.2% Net loss $27.28M Diluted EPS -$0.98

May 22